ବ୍ୟବହାରକାରୀ:Doc James/Test

Doc James/Test
Clinical data
Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
data	EU EMA: yes; US DailyMed: Pazopanib;
Pregnancy; category	AU: D ; US: D (Evidence of risk) ;
Routes of; administration	By mouth (tablets)
Drug class	Tyrosine kinase inhibitor
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
	IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide;
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	୪୩୭.୫୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C;
	InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H ; Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N ;
(what is this?) (verify)

Pazopanib, sold under the brand name Votrient, is a medication used to treat renal cell carcinoma (RCC) and certain soft tissue sarcoma.^[୪] In RCC it is used when other treatments have failed.^[୪] It is taken by mouth.^[୪]

Common side effects include diarrhea, high blood pressure, white hair, nausea, tiredness, abdominal pain, low blood cells, and liver problems.^[୧] Other side effects may include low thyroid, QT prolongation, bleeding, blood clots, and gastrointestinal perforation.^[୧] Use during pregnancy may harm the baby.^[୧] It is a tyrosine kinase inhibitor.^[୧]

Pazopanib was approved for medical use in the United States in 2009.^[୧] In Europe it received conditional approval in 2010 and full approval in 2013.^[୫] In the United Kingdom it costs the NHS about £2,250 per month as of 2021.^[୪] In the United States this amount costs about 14,200 USD.^[୬]

References

1 2 3 4 5 6 "PAZOPanib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 26 October 2021.
1 2 3 "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.
1 2 3 "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 27 January 2014.
1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.
↑ "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.
↑ "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.

[AHFS2021-1] 1 2 3 4 5 6 "PAZOPanib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 26 October 2021.

[EMA_CHMP-2] 1 2 3 "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.

[MSR-3] 1 2 3 "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 27 January 2014.

[BNF81-4] 1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.

[EPAR2021-5] "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.

[6] "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]